Genentech Enspryng cuts MOGAD relapse risk 68%
See more from StockTitan in Google Search and AI answers.
Adds StockTitan as…
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary…
EHA26: AstraZeneca battles Roche in untreated follicular lymphoma
At the 2026 European Hematological Association (EHA) conference, held in Stockholm on 11–14 June, AstraZeneca shared preliminary safety…
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary…
Novartis Reports Positive Data for Neuromuscular Disorder Drug
Novartis NVS announced positive data from the biomarker cohort of the FORTITUDE phase I/II study. The FORTITUDE phase…
Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint
Novartis Pharma AG Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary…
Roche breast cancer pill gets FDA priority review
Roche (OTCQX:RHHBY) reported that the US FDA accepted, under Priority Review, its New…
Genentech fenebrutinib cuts relapsing MS relapses 51%-59%
04/21/2026 – 07:15 PM Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib…
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
F. Hoffmann-La Roche Ltd Basel, 13 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that…
Roche giredestrant NDA accepted by FDA for breast cancer
Roche (OTCQX: RHHBY) announced FDA acceptance of its New Drug Application for giredestrant…
Novartis reports final data of ALIGN trial in IgAN
Novartis has announced final data from the Phase III ALIGN study, highlighting that Vanrafia (atrasentan) slowed kidney function…
Roche oral SERD giredestrant boosts iDFS in early breast cancer
Roche (OTCQX: RHHBY) reported positive Phase III results from the lidERA trial of…